A Plasma-Based DNA Test for Quantification of Disease Burden in Acute Myeloid Leukemia Patients Undergoing Bone Marrow Transplantation

Why It Matters

The v96 assay offers a non‑invasive, highly sensitive method to track measurable residual disease, enabling earlier intervention and potentially improving transplant outcomes. Its superior detection could reshape AML monitoring standards and reduce reliance on bone‑marrow biopsies.

Key Takeaways

• v96 assay tracks up to 96 patient‑specific AML mutations in plasma.
• 30 patients showed residual disease by v96, versus 20% by conventional assays.
• Plasma cfDNA revealed 352‑fold higher mutant load in relapsers pre‑transplant.
• Post‑transplant MRD drop occurred after immunosuppression stop, indicating graft‑versus‑leukemia.

Pulse Analysis

Acute myeloid leukemia (AML) remains a lethal disease where allogeneic hematopoietic stem cell transplantation offers the only curative path for many patients. Yet, the success of transplantation hinges on precise measurement of measurable residual disease (MRD) before and after the procedure. Traditional MRD assessments rely on bone‑marrow biopsies and flow cytometry, which are invasive, subject to sampling error, and often lack the sensitivity needed to detect low‑level disease that predicts relapse. The emergence of circulating tumor DNA (ctDNA) technologies promises a less invasive window into tumor genetics, but prior assays have been limited by narrow mutation panels and insufficient analytical depth.

The newly reported v96 assay expands the ctDNA toolkit by targeting up to 96 patient‑specific mutations, leveraging deep next‑generation sequencing of plasma cell‑free DNA. In a prospective study of 30 AML transplant recipients, v96 identified residual leukemia in every patient during remission, a stark contrast to the 20% detection rate of standard clinical assays. Moreover, plasma cfDNA outperformed bone‑marrow cellular DNA, with relapsing patients exhibiting a 352‑fold increase in mutant allele burden before transplant. Post‑transplant monitoring revealed that MRD levels fell after immunosuppression cessation, underscoring the assay’s ability to capture graft‑versus‑leukemia effects in real time. These findings demonstrate that a broad, highly specific mutation panel can deliver the sensitivity and specificity required for actionable MRD surveillance.

If integrated into clinical workflows, v96 could transform AML management by reducing the need for repeated bone‑marrow biopsies, enabling earlier therapeutic adjustments, and informing optimal timing for transplantation and maintenance strategies. The assay’s scalability and compatibility with existing sequencing platforms position it for rapid adoption, while ongoing prospective trials will be essential to validate its predictive power across diverse AML subtypes. Ultimately, such non‑invasive MRD tools may set new standards for precision oncology, improving patient outcomes and lowering healthcare costs associated with invasive procedures.